Hepion Pharmaceuticals Inc. (HEPA) is primed for evolution with the beta value of 1.90

investchronicle 92

At the end of the latest market close, Hepion Pharmaceuticals Inc. (HEPA) was valued at $3.50. In that particular session, Stock kicked-off at the price of $3.54 while reaching the peak value of $3.65 and lowest value recorded on the day was $3.455. The stock current value is $3.56.

Recently in News on August 27, 2020, Hepion Pharmaceuticals to Present CRV431 Preclinical Data at the 2020 Digital International Liver Congress(TM). EDISON, NJ / ACCESSWIRE / August 27, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) “Hepion”, a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”), today announced that it will present a poster on CRV431’s antifibrotic activity at the Digital International Liver Congress™ 2020 (EASL), taking place from August 27-29, 2020. You can read further details here

Hepion Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $6.90 on 01/29/20, with the lowest value was $1.00 for the same time period, recorded on 03/18/20.

Hepion Pharmaceuticals Inc. (HEPA) full year performance was 44.63%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Hepion Pharmaceuticals Inc. shares are logging -57.33% during the 52-week period from high price, and 256.28% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.00 and $8.35.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 690068 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Hepion Pharmaceuticals Inc. (HEPA) recorded performance in the market was -34.70%, having the revenues showcasing 87.17% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 31.36M, as it employees total of 12 workers.

Market experts do have their say about Hepion Pharmaceuticals Inc. (HEPA)

During the last month, 0 analysts gave the Hepion Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.70, with a change in the price was noted +2.02. In a similar fashion, Hepion Pharmaceuticals Inc. posted a movement of +124.69% for the period of last 100 days, recording 1,358,796 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for HEPA is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.01.

Technical breakdown of Hepion Pharmaceuticals Inc. (HEPA)

Raw Stochastic average of Hepion Pharmaceuticals Inc. in the period of last 50 days is set at 53.70%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 15.60%. In the last 20 days, the company’s Stochastic %K was 7.32% and its Stochastic %D was recorded 6.72%.

Bearing in mind the latest performance of Hepion Pharmaceuticals Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -34.70%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -14.63%, alongside a boost of 44.63% for the period of the last 12 months. The shares increased approximately by -5.41% in the 7-day charts and went up by -13.15% in the period of the last 30 days. Common stock shares were driven by 87.17% during last recorded quarter.